Bioaffinity Technologies, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. (Nasdaq: BIAF) on November 30, 2023. The filing reports a significant regulatory milestone regarding the Company's noninvasive early-stage lung cancer test, CyPath® Lung.
Key Financial Metrics and Pricing
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics. However, it details specific pricing and reimbursement data for the CyPath® Lung test:
- Historical Reimbursement (Pre-Oct 2023): Approximately $300 using a combination of flow cytometry CPT codes.
- Historical Fee Schedule Price: $905 based on Medicare reimbursement using existing codes.
- Current Billing Rate (Q4 2023): $1,900 per test, based on a preliminary crosswalk to CPT code 0021U ($760 payment).
- 2024 Status: Finalized payment determination for CPT code 0406U effective January 1, 2024.
Material Changes
The primary material change is the finalization of the Centers for Medicare and Medicaid Services (CMS) payment determination for CyPath® Lung for the 2024 calendar year. Key developments include:
- CPT Code Assignment: In June 2023, the American Medical Association assigned CPT code 0406U specifically for CyPath® Lung, effective October 1, 2023.
- Payment Finalization: CMS finalized the 2024 payment determination in November 2023, moving from a preliminary decision in September 2023.
- Fee Schedule Inclusion: CyPath® Lung is now included on the CMS 2024 Clinical Laboratory Fee Schedule, serving as a reference for private payers and other public health programs.
Outlook, Risks, and Management Commentary
Management views the finalization of the CMS payment as a critical step for commercialization. The 2024 Medicare payment rate will serve as a benchmark for private payers. The filing includes "safe harbor" language indicating that forward-looking statements regarding future reimbursement and commercial success are subject to risks and uncertainties. The Company undertakes no obligation to update this information.
Investor Verification Checklist
- Verify the specific dollar amount of the finalized 2024 CMS payment rate for CPT code 0406U (the filing confirms the decision was made but does not explicitly state the final 2024 dollar figure in the text provided).
- Confirm the adoption rate of the new CPT code 0406U by private payers versus the previous flow cytometry codes.
- Review the attached press release (Exhibit 99.1) for detailed forward-looking statements regarding revenue projections.
- Monitor the Company's ability to transition billing systems to the new CPT code and the associated $1,900 billing rate.